Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/EPAR/ebglysshttps://www.ema.europa.eu/en/medicines/human/EPAR/ebglyss
Retrieved on: 
Monday, December 18, 2023
Information
Tags: 
People, Eye, Allergic conjunctivitis, Select, Anatomy, ATC, Safety, European Medicines Agency, Ageing, International, IGA, INN, Disease, Language, Overview, Dry, Patient, IIA, Thigh, Conjunctivitis, Marketing, EASI, Atopic dermatitis, Medical Subject Headings, Diagnosis, Red, Skin, Human, Inflammation, Instrumentation, Medicinal plants, Medical device, Copper, Vaccine, Medical imaging, Online shopping, Bookkeeping, Dermatitis, Medicine
Geotags: 
EU
Summary
Key Points: 


Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Copyright: 
2023 European Medicines Agency. All Rights Reserved.